Compare · NVO vs STTK
NVO vs STTK
Side-by-side comparison of Novo Nordisk A/S (NVO) and Shattuck Labs Inc. (STTK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and STTK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 546.2x STTK ($351.2M).
- Over the past year, NVO is down 45.2% and STTK is up 225.1% - STTK leads by 270.3 points.
- STTK has been more active in the news (12 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 13 for STTK).
- Company
- Novo Nordisk A/S
- Shattuck Labs Inc.
- Price
- $41.34-3.73%
- $3.88-15.36%
- Market cap
- $191.82B
- $351.2M
- 1M return
- -9.69%
- -37.94%
- 1Y return
- -45.20%
- +225.10%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 8
- 12
- Recent ratings
- 25
- 13
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Shattuck Labs Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest STTK
- Shattuck Labs Announces Phase 1 Results for SL-325
- Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
- SEC Form 4 filed by Director Golumbeski George
- SEC Form 4 filed by Director Ashiya Mona
- SEC Form 4 filed by Director Baker Daniel G.
- SEC Form 4 filed by Director Siegall Clay B
- SEC Form 4 filed by Director Gibson Neil W
- SEC Form 4 filed by Director Boudreau Helen M
- SEC Form 8-K filed by Shattuck Labs Inc.
- Director Siegall Clay B was granted 128,054 shares, increasing direct ownership by 100% to 256,108 units (SEC Form 4)